We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Microsatellite Genotyping Reveals Signature in Breast Cancer Exomes

By LabMedica International staff writers
Posted on 24 Jul 2014
Print article
Image: Histopathology of high grade invasive ductal carcinoma of the breast (Photo courtesy of Johns Hopkins University).
Image: Histopathology of high grade invasive ductal carcinoma of the breast (Photo courtesy of Johns Hopkins University).
Several novel markers have been pinpointed in breast cancer (BC) patients that may not only reveal risks for the disease, but may yield therapeutic benefits as well.

Microsatellites are repetitive DNA regions that occur throughout the genome, and variations within microsatellites can affect cellular function through mechanisms including promoting altering protein sequence and affecting gene regulation.

Scientists at Virginia Tech (Blacksburg, VA, USA) computed the genotypes of microsatellite loci found within 249 ethnically matched healthy female germlines, 656 BC germline exomes, 689 BC tumors (656 matched to the germline samples), and 212 healthy male germlines from exome sequences that were available. The genotypes at these loci created a profile used as a risk assessment tool for classifying independent sets of the healthy or BC exomes.

The team applied their microsatellite genotyping pipeline to nearly 50,000 microsatellite loci from BC and disease-free females and identified 55 loci at which the frequency of nonmodal genotypes was statistically significantly different between the two populations, of which 30 showed a risk ratio below 0.6, while 25 had a risk ratio greater than 1.3. The overwhelming majority of exomes classified as cancer-like did not carry any known BC-associated mutation. An assay consisting of these 55 loci could be clinically informative with a sensitivity of 88.4 %, which exceeds current test performance, while the specificity is about two fold which would be expected, given that 12 % of the healthy female population will be future BC patients.

Natalie Fonville, PhD, a geneticist and coauthor of the study said, “There is still a lot we can learn from looking at the human genome and how it can be affected in ways that may be associated with disease. This study is the first of many in which we are engaged that identify subtle genomic changes which together may add up to cancer risk.”

Michael B. Waitzkin, JD, the chief executive officer of Genomeon LLC (Floyd, VA, USA) to whom the technology has been licensed, said, “The use of microsatellite variations as diagnostics has the potential to transform the way cancer and other heritable diseases are diagnosed and treated. This technology is a very exciting example of the possibilities for translating academic discoveries into clinical use.” The study was published in the June 2014 issue of the journal Breast Cancer Research and Treatment.

Related Links:

Virginia Tech
Genomeon LLC



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.